Financial News Based On Company



Advertisement

$100 Invested In Cencora 10 Years Ago Would Be Worth This Much Today - Cencora ( NYSE:COR )

https://www.benzinga.com/insights/news/25/06/46096709/100-invested-in-cencora-10-years-ago-would-be-worth-this-much-today
Cencora COR has outperformed the market over the past 10 years by 8.18% on an annualized basis producing an average annual return of 19.61%. Currently, Cencora has a market capitalization of $57.01 billion.

GEHC Stock Gains Post FDA's Nod for Vizamyl's Expanded Indications

https://www.zacks.com/stock/news/2553699/gehc-stock-gains-post-fdas-nod-for-vizamyls-expanded-indications
GE HealthCare gains FDA nod to expand Vizamyl's use, unlocking new diagnostic and therapy-monitoring capabilities.

Should You Continue to Retain Abbott Stock in Your Portfolio Now?

https://www.zacks.com/stock/news/2544438/should-you-continue-to-retain-abbott-stock-in-your-portfolio-now
ABT rides on strong global demand in diagnostics and diabetes care, but macro headwinds may test its momentum ahead.

Is This the Right Time to Hold EYE Stock in Your Portfolio?

https://www.zacks.com/stock/news/2543950/is-this-the-right-time-to-hold-eye-stock-in-your-portfolio
National Vision gains from America's Best momentum and strategic revamp, but solvency issues and rising costs weigh on profitability.

TNDM Stock Gains on t:slim X2's Compatibility With FreeStyle Libre 3 +

https://www.zacks.com/stock/news/2535451/tndm-stock-gains-on-tslim-x2s-compatibility-with-freestyle-libre-3-
Tandem Diabetes' t:slim X2 pump with Control-IQ+ tech gains U.S. early access using FreeStyle Libre 3 Plus sensor.
Advertisement

Advertisement

QIAGEN's New QIAcuity dPCR IVD Pact With GENCURIX May Boost Its Stock

https://www.zacks.com/stock/news/2514652/qiagens-new-qiacuity-dpcr-ivd-pact-with-gencurix-may-boost-its-stock
QGEN teams with GENCURIX to expand its digital PCR IVD offerings, aiming to strengthen its precision diagnostics arm.

ABT's i-STAT TBI Test Receives Approval in Canada: Stock to Rise?

https://www.zacks.com/stock/news/2514587/abts-i-stat-tbi-test-receives-approval-in-canada-stock-to-rise
Abbott gains Health Canada approval for its i-STAT TBI test, enabling rapid bedside concussion detection via whole blood.

Should You Add NVST Stock to Your Portfolio Right Now?

https://www.zacks.com/stock/news/2514586/should-you-add-nvst-stock-to-your-portfolio-right-now
Envista's global expansion, smart acquisitions, and strong balance sheet support growth but forex risks remain a drag.

Unpacking the Latest Options Trading Trends in Cardinal Health - Cardinal Health ( NYSE:CAH )

https://www.benzinga.com/insights/options/25/06/46000612/unpacking-the-latest-options-trading-trends-in-cardinal-health
Investors with a lot of money to spend have taken a bullish stance on Cardinal Health CAH. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.

Reasons to Add PAHC Stock to Your Portfolio Right Now

https://www.zacks.com/stock/news/2510517/reasons-to-add-pahc-stock-to-your-portfolio-right-now
Phibro's strong Animal Health momentum and global expansion bode well for investors.
Advertisement

Advertisement

Labcorp Stock Climbs 25.6% This Year: What's Driving the Surge?

https://www.zacks.com/stock/news/2510266/labcorp-stock-climbs-256-this-year-whats-driving-the-surge
LH stock surges 25.6% this year, powered by specialty testing expansion, key acquisitions and solid financials.

$100 Invested In Cencora 5 Years Ago Would Be Worth This Much Today - Cencora ( NYSE:COR )

https://www.benzinga.com/insights/news/25/06/45984878/100-invested-in-cencora-5-years-ago-would-be-worth-this-much-today
Cencora COR has outperformed the market over the past 5 years by 9.6% on an annualized basis producing an average annual return of 23.58%. Currently, Cencora has a market capitalization of $56.83 billion.

DGX Stock Up on New Blood Test Development Deal With MD Anderson

https://www.zacks.com/stock/news/2506147/dgx-stock-up-on-new-blood-test-development-deal-with-md-anderson
DGX stock rises on a new partnership with MD Anderson to develop a blood test targeting multiple cancer risks.

GEHC Stock Declines Despite Expansion in Precision Care Capabilities

https://www.zacks.com/stock/news/2503766/gehc-stock-declines-despite-expansion-in-precision-care-capabilities
GE HealthCare integrates proprietary algorithms into MIM Encore to advance digital imaging and workflow precision.

Take the Zacks Approach to Beat the Markets: Mirion Technologies, Avino Silver & Gold Mines, Quanta Services in Focus

https://www.zacks.com/stock/news/2503297/take-the-zacks-approach-to-beat-the-markets-mirion-technologies-avino-silver-gold-mines-quanta-services-in-focus
MIR, ASM and PWR outperform the S&P 500 after Zacks upgrades, spotlighting key stock picks in a volatile market.
Advertisement

Advertisement

QGEN Stock Rises in After Market Following Partnership With Incyte

https://www.zacks.com/stock/news/2503105/qgen-stock-rises-in-after-market-following-partnership-with-incyte
QIAGEN teams up with Incyte to develop NGS-based companion diagnostics for blood cancers.

Should You Hold Myriad Genetics Stock in Your Portfolio Right Now?

https://www.zacks.com/stock/news/2503102/should-you-hold-myriad-genetics-stock-in-your-portfolio-right-now
MYGN sees growth in oncology and women's health testing, but GeneSight coverage loss clouds the near-term outlook.

Should You Add QIAGEN Stock to Your Portfolio for Now?

https://www.zacks.com/stock/news/2498546/should-you-add-qiagen-stock-to-your-portfolio-for-now
QGEN rides on test menu growth, strategic partnerships, and strong solvency, despite macro and market headwinds.

STARS LIGHT UP THE NIGHT SKY AS NORTH SHORE ANIMAL LEAGUE AMERICA'S "CELEBRATION OF RESCUE" GALA ROCKS DOWNTOWN NYC IN HONOR OF ANIMAL RESCUE AND ADOPTION

https://www.benzinga.com/pressreleases/25/06/n45921351/stars-light-up-the-night-sky-as-north-shore-animal-league-americas-celebration-of-rescue-gala-rock
NEW YORK, June 13, 2025 /PRNewswire/ -- North Shore Animal League America, the world's largest no-kill animal rescue and adoption organization, hosted their annual "Celebration of Rescue" Gala on Thursday, June 12 at the spectacular TriBeCa Rooftop under the stars, overlooking the shimmering ...

Cardinal Health Analyst Flags Fading Scale Gap, Sees Rising Edge in Specialty Growth - Cardinal Health ( NYSE:CAH )

https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45890484/cardinal-health-analyst-flags-fading-scale-gap-sees-rising-edge-in-specialty-
Analyst expects Cardinal Health to raise long-term pharma EBIT growth target to as high as 5%-8%. Investor day to highlight specialty investments, tariff mitigation, and balanced capital strategy. Get access to the leaderboards pointing to tomorrow's biggest stock movers.
Advertisement

Advertisement

Should You Continue to Hold Prestige Consumer Stock in Your Portfolio?

https://www.zacks.com/stock/news/2494085/should-you-continue-to-hold-prestige-consumer-stock-in-your-portfolio
PBH rides strong on e-commerce gains and brand innovations, but debt load and forex risks cast a shadow on future growth.

Bruker Stock Set to Gain From Acquisition of Austria's biocrates

https://www.zacks.com/stock/news/2492104/bruker-stock-set-to-gain-from-acquisition-of-austrias-biocrates
BRKR strengthens its MS-based metabolomics platform with the biocrates deal, boosting investor sentiment.

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ ( bevacizumab gamma ) for the Treatment of Wet AMD

https://www.globenewswire.com/news-release/2025/06/10/3096601/0/en/Outlook-Therapeutics-Announces-SMC-Recommendation-of-LYTENAVA-bevacizumab-gamma-for-the-Treatment-of-Wet-AMD.html
ISELIN, N.J., June 10, 2025 ( GLOBE NEWSWIRE ) -- Outlook Therapeutics, Inc. ( Nasdaq: OTLK ) , a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the Scottish Medicines Consortium ( SMC ) acceptance of ...

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ ( bevacizumab gamma ) for the Treatment of Wet AMD - Outlook Therapeutics ( NASDAQ:OTLK )

https://www.benzinga.com/pressreleases/25/06/g45857507/outlook-therapeutics-announces-smc-recommendation-of-lytenava-bevacizumab-gamma-for-the-treatment-
ISELIN, N.J., June 10, 2025 ( GLOBE NEWSWIRE ) -- Outlook Therapeutics, Inc.

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ ( bevacizumab gamma ) for the Treatment of Wet AMD

https://markets.businessinsider.com/news/stocks/outlook-therapeutics-announces-smc-recommendation-of-lytenava-bevacizumab-gamma-for-the-treatment-of-wet-amd-1034809487
Outlook Therapeutics® Announces SMC Recommendation of LYTENAVAâ„¢ (bevacizumab gamma) for the Treatment of Wet ...
Advertisement

Advertisement

Is Invesco S&P 500 Equal Weight Health Care ETF ( RSPH ) a Strong ETF Right Now?

https://www.zacks.com/stock/news/2490319/is-invesco-sp-500-equal-weight-health-care-etf-rsph-a-strong-etf-right-now
Smart Beta ETF report for ...

ECL Stock Gains Following Latest Launch to Boost Data Center Cooling

https://www.zacks.com/stock/news/2486134/ecl-stock-gains-following-latest-launch-to-boost-data-center-cooling
Ecolab's 3D TRASAR technology expands its cooling solutions, aiming to optimize data centers and cut resource demand.

Should You Continue to Hold EXAS Sciences Stock in Your Portfolio?

https://www.zacks.com/stock/news/2485577/should-you-continue-to-hold-exas-sciences-stock-in-your-portfolio
EXAS rides on strong Cologuard and Oncotype DX growth, but rising costs and high debt may test its staying power.

Is iShares MSCI USA Equal Weighted ETF ( EUSA ) a Strong ETF Right Now?

https://www.zacks.com/stock/news/2485412/is-ishares-msci-usa-equal-weighted-etf-eusa-a-strong-etf-right-now
Smart Beta ETF report for ...

HIMS Stock Falls Despite Latest Deal to Expand International Footprint

https://www.zacks.com/stock/news/2484774/hims-stock-falls-despite-latest-deal-to-expand-international-footprint
Hims & Hers is set to acquire ZAVA to launch in Germany, France and Ireland, deepening its personalized digital health push.
Advertisement

Advertisement

Should You Continue to Hold Labcorp Stock in Your Portfolio?

https://www.zacks.com/stock/news/2484199/should-you-continue-to-hold-labcorp-stock-in-your-portfolio
LH's growth focus and financial strength look promising, but can it navigate rising competition and macro headwinds?

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today - Cencora ( NYSE:COR )

https://www.benzinga.com/insights/news/25/06/45761586/100-invested-in-this-stock-5-years-ago-would-be-worth-this-much-today
Cencora COR has outperformed the market over the past 5 years by 10.28% on an annualized basis producing an average annual return of 23.3%. Currently, Cencora has a market capitalization of $56.51 billion.

QGEN Stock to Gain From Expanding Oncology Portfolio via New Alliances

https://www.zacks.com/stock/news/2482253/qgen-stock-to-gain-from-expanding-oncology-portfolio-via-new-alliances
QIAGEN expands the oncology portfolio with new MRD testing alliances, setting the stage for personalized cancer care and stock growth.

Is Cencora, Inc. ( COR ) Stock Outpacing Its Medical Peers This Year?

https://www.zacks.com/stock/news/2480251/is-cencora-inc-cor-stock-outpacing-its-medical-peers-this-year
Here is how Cencora (COR) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.

Charles River Stock May Gain From Extended CHDI Research Deal on HD

https://www.zacks.com/stock/news/2480029/charles-river-stock-may-gain-from-extended-chdi-research-deal-on-hd
CRL and CHDI Foundation extend their Huntington's disease partnership, boosting integration and global flexibility in drug discovery.
Advertisement

Advertisement

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ ( bevacizumab gamma ) in Germany and the UK for the Treatment of Wet AMD - Outlook Therapeutics ( NASDAQ:OTLK )

https://www.benzinga.com/pressreleases/25/06/g45717741/outlook-therapeutics-announces-commercial-launch-of-lytenava-bevacizumab-gamma-in-germany-and-the-
LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union ( EU ) and United Kingdom ( UK ) 2.8 million injections of repackaged off-label bevacizumab in Europe each year1

COO Q2 Earnings Beat, 2025 Sales Outlook Tightened, Stock Down

https://www.zacks.com/stock/news/2479449/coo-q2-earnings-beat-2025-sales-outlook-tightened-stock-down
COO's fiscal Q2 earnings and sales beat market expectations on the back of strong growth. Improvement in operating margin bodes well.

Here's Why You Should Add Cencora Stock to Your Portfolio Now

https://www.zacks.com/stock/news/2479450/heres-why-you-should-add-cencora-stock-to-your-portfolio-now
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

What's Driving the Market Sentiment Around Cencora? - Cencora ( NYSE:COR )

https://www.benzinga.com/insights/short-sellers/25/05/45680628/whats-driving-the-market-sentiment-around-cencora
Cencora's COR short percent of float has fallen 8.83% since its last report. The company recently reported that it has 6.06 million shares sold short, which is 5.37% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.87 days to cover their ...

Reasons to Retain The Cooper Companies Stock in Your Portfolio Now

https://www.zacks.com/stock/news/2478793/reasons-to-retain-the-cooper-companies-stock-in-your-portfolio-now
COO benefits from the strength in its business segments. Its acquisitions are likely to drive the top line. However, a rise in selling, general and administrative expenses is concerning.
Advertisement

Advertisement

Hims & Hers Stock Falls Despite the Latest Wegovy Availability Offer

https://www.zacks.com/stock/news/2478488/hims-hers-stock-falls-despite-the-latest-wegovy-availability-offer
HIMS launches six-month Wegovy access at $549/month, aiming to expand affordable obesity care with holistic weight loss solutions.

Here's Why You Should Add Inogen Stock to Your Portfolio Now

https://www.zacks.com/stock/news/2478116/heres-why-you-should-add-inogen-stock-to-your-portfolio-now
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.

Beat the Market the Zacks Way: GE Aerospace, Monster Beverage, Cencora in Focus

https://www.zacks.com/stock/news/2477597/beat-the-market-the-zacks-way-ge-aerospace-monster-beverage-cencora-in-focus
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Here's Why You Should Retain CONMED Stock in Your Portfolio for Now

https://www.zacks.com/stock/news/2476902/heres-why-you-should-retain-conmed-stock-in-your-portfolio-for-now
CNMD stock rides high on strong recurring revenues, margin gains, and surgical product growth despite supply and cybersecurity challenges.

RVTY Stock Falls Despite the Latest Launch of Automated Instrument

https://www.zacks.com/stock/news/2476699/rvty-stock-falls-despite-the-latest-launch-of-automated-instrument
Revvity unveils IDS i20, a fully automated immunodiagnostics platform designed to enhance lab efficiency and expand specialty testing.
Advertisement

Advertisement

Should iShares Russell Mid-Cap Growth ETF ( IWP ) Be on Your Investing Radar?

https://www.zacks.com/stock/news/2476460/should-ishares-russell-mid-cap-growth-etf-iwp-be-on-your-investing-radar
Style Box ETF report for ...

Here's Why Investors Should Consider Retaining Danaher Stock Now

https://www.zacks.com/stock/news/2476138/heres-why-investors-should-consider-retaining-danaher-stock-now
DHR gains from strength across its businesses, acquired assets and shareholder-friendly policies. High long-term debt remains concerning.

Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF ( RSPH ) ?

https://www.zacks.com/stock/news/2475709/should-you-invest-in-the-invesco-sp-500-equal-weight-health-care-etf-rsph
Sector ETF report for ...

MMSI Stock Gains Following Latest Merger to Boost Hemostasis Portfolio

https://www.zacks.com/stock/news/2475594/mmsi-stock-gains-following-latest-merger-to-boost-hemostasis-portfolio
Merit Medical aims to provide an additional effective solution that complements a wide range of percutaneous procedures, including interventional radiology and cardiology.

Here's Why You Should Retain Glaukos Stock in Your Portfolio

https://www.zacks.com/stock/news/2475121/heres-why-you-should-retain-glaukos-stock-in-your-portfolio
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.
Advertisement

Advertisement

Advertisement